Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions
SMMT Stock Forecast
Summit Therapeutics stock forecast is as follows: an average price target of $29.50 (represents a 12.55% upside from SMMT’s last price of $26.21) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
SMMT Price Target
The average price target for Summit Therapeutics (SMMT) is $29.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $14.00. This represents a potential 12.55% upside from SMMT's last price of $26.21.
SMMT Analyst Ratings
According to 2 Wall Street analysts, Summit Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SMMT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Summit Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Mitchell Kapoor | H.C. Wainwright | $45.00 | $31.93 | 40.93% | 71.69% |
| Jun 03, 2024 | Brad Canino | Stifel Nicolaus | $14.00 | $8.69 | 61.20% | -46.59% |
| Mar 25, 2024 | Brad Canino | Stifel Nicolaus | $8.00 | $3.28 | 143.90% | -69.48% |
The latest Summit Therapeutics stock forecast, released on Sep 16, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $45.00, which represents a 40.93% increase from the stock price at the time of the forecast ($31.93), and a 71.69% increase from SMMT last price ($26.21).
Summit Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $45.00 | $45.00 | $22.33 |
| Last Closing Price | $26.21 | $26.21 | $26.21 |
| Upside/Downside | 71.69% | 71.69% | -14.80% |
In the current month, the average price target of Summit Therapeutics stock is $45.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 71.69% increase as opposed to Summit Therapeutics's last price of $26.21. This month's average price target is down 0.00% compared to last quarter, and up 101.52% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jul 19, 2024 | Citigroup | Buy | Buy | Hold |
| May 31, 2024 | Citigroup | Buy | Buy | Hold |
| May 07, 2024 | Citigroup | - | Buy | Initialise |
Summit Therapeutics's last stock rating was published by Citigroup on Sep 09, 2024. The company gave SMMT a "Buy" rating, the same as its previous rate.
Summit Therapeutics Financial Forecast
Summit Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.31M | $57.00K | $192.00K | $185.00K | $181.00K | $170.00K | $312.96K | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $9.74M | $1.71K | $4.45M | $4.41M | $3.94M | $4.08M | $4.00M | $5.13M | $4.97M | $218.83K | $693.39K | $346.83M | $6.97M | $3.40M | $28.47M | $1.36M |
| High Forecast | - | - | - | - | - | - | - | - | $9.74M | $2.05K | $4.45M | $4.41M | $3.94M | $4.08M | $4.00M | $5.13M | $4.97M | $262.59K | $832.07K | $416.20M | $8.36M | $4.08M | $34.16M | $1.63M |
| Low Forecast | - | - | - | - | - | - | - | - | $9.74M | $1.36K | $4.45M | $4.41M | $3.94M | $4.08M | $4.00M | $5.13M | $4.97M | $175.06K | $554.71K | $277.47M | $5.58M | $2.72M | $22.77M | $1.09M |
| # Analysts | - | - | - | - | - | - | - | - | 1 | 17 | 10 | 16 | 11 | 8 | 7 | 10 | 9 | 14 | 9 | 9 | 7 | 19 | 11 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 767.29% | 0.01% | 0.04% | 0.05% | 0.04% | 0.04% | 0.06% | - | - | - | - | - | - | - | - |
Summit Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $9.74M, with a low forecast of $9.74M, and a high forecast of $9.74M. SMMT's average Quarter revenue forecast represents a 644.20% increase compared to the company's last Quarter revenue of $1.31M (Sep 21).
Summit Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 17 | 10 | 16 | 11 | 8 | 7 | 10 | 9 | 14 | 9 | 9 | 7 | 19 | 11 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-18.97M | $-23.75M | $-17.00M | $-13.27M | $-17.34M | $-14.91M | $-6.90M | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $-5.84M | $-24.72M | $-13.06M | $-2.64M | $-2.37M | $-1.90B | $-2.40M | $-3.08M | $-2.98M | $-8.52M | $-8.81M | $251.76M | $-11.35M | $-5.87M | $14.86M | $-12.45M |
| High Forecast | - | - | - | - | - | - | - | - | $-5.84M | $-19.78M | $-10.45M | $-2.64M | $-2.37M | $-1.52B | $-2.40M | $-3.08M | $-2.98M | $-6.81M | $-7.05M | $302.11M | $-9.08M | $-4.70M | $17.83M | $-9.96M |
| Low Forecast | - | - | - | - | - | - | - | - | $-5.84M | $-29.67M | $-15.68M | $-2.64M | $-2.37M | $-2.28B | $-2.40M | $-3.08M | $-2.98M | $-10.22M | $-10.58M | $201.41M | $-13.62M | $-7.04M | $11.89M | $-14.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.77% | 1.82% | 6.43% | 5.60% | 0.01% | 6.21% | 2.24% | - | - | - | - | - | - | - | - |
undefined analysts predict SMMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Summit Therapeutics's previous annual EBITDA (undefined) of $NaN.
Summit Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 17 | 10 | 16 | 11 | 8 | 7 | 10 | 9 | 14 | 9 | 9 | 7 | 19 | 11 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-19.71M | $-25.10M | $-18.05M | $-13.44M | $-17.70M | $-15.28M | $-6.11M | - | - | - | - | - | - | - | - |
| Avg Forecast | $-44.64M | $-41.85M | $-36.27M | $-36.27M | $-37.24M | $-37.33M | $-34.60M | $-33.54M | $1.17B | $-25.55M | $-13.43M | $-86.31M | $-108.23M | $-1.94B | $-50.66M | $-14.29M | $-119.35M | $-9.43M | $-7.88M | $243.50M | $-10.50M | $-3.49M | $16.40M | $-10.82M |
| High Forecast | $-44.64M | $-41.85M | $-36.27M | $-36.27M | $-37.24M | $-32.00M | $-34.60M | $-33.54M | $1.17B | $-20.44M | $-10.74M | $-86.31M | $-108.23M | $-1.55B | $-50.66M | $-14.29M | $-119.35M | $-7.54M | $-6.30M | $292.20M | $-8.40M | $-2.79M | $19.69M | $-8.66M |
| Low Forecast | $-44.64M | $-41.85M | $-36.27M | $-36.27M | $-37.24M | $-37.33M | $-34.60M | $-33.54M | $1.17B | $-30.66M | $-16.11M | $-86.31M | $-108.23M | $-2.33B | $-50.66M | $-14.29M | $-119.35M | $-11.31M | $-9.46M | $194.80M | $-12.60M | $-4.18M | $13.12M | $-12.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.77% | 1.87% | 0.21% | 0.12% | 0.01% | 0.30% | 0.43% | - | - | - | - | - | - | - | - |
Summit Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SMMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Summit Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 17 | 10 | 16 | 11 | 8 | 7 | 10 | 9 | 14 | 9 | 9 | 7 | 19 | 11 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $5.66M | $5.98M | $4.18M | $5.80M | $7.46M | $5.77M | $646.95K | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $173.48M | $30.38K | $3.29M | $78.48M | $70.25M | $72.60M | $71.23M | $91.29M | $88.58M | $3.90M | $12.35M | $24.73M | $4.80M | $60.53M | $3.74M | $24.23M |
| High Forecast | - | - | - | - | - | - | - | - | $173.48M | $36.43K | $3.95M | $78.48M | $70.25M | $72.60M | $71.23M | $91.29M | $88.58M | $4.68M | $14.82M | $29.68M | $5.76M | $72.63M | $4.48M | $29.08M |
| Low Forecast | - | - | - | - | - | - | - | - | $173.48M | $24.29K | $2.63M | $78.48M | $70.25M | $72.60M | $71.23M | $91.29M | $88.58M | $3.12M | $9.88M | $19.79M | $3.84M | $48.42M | $2.99M | $19.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 186.38% | 1.82% | 0.05% | 0.08% | 0.10% | 0.08% | 0.01% | - | - | - | - | - | - | - | - |
Summit Therapeutics's average Quarter SG&A projection for Dec 23 is $173.48M, based on 1 Wall Street analysts, with a range of $173.48M to $173.48M. The forecast indicates a 2963.85% rise compared to SMMT last annual SG&A of $5.66M (Sep 21).
Summit Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Dec 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | 17 | 10 | 16 | 11 | 8 | 7 | 10 | 9 | 14 | 9 | 9 | 7 | 19 | 11 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.20 | $-0.28 | $-0.22 | $-0.18 | $-0.26 | $-0.23 | $-0.09 | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.06 | $-0.06 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $1.65 | $-0.21 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.67 | $-0.18 | $-1.96 | $-0.75 | $-0.65 | $0.30 | $4.74 |
| High Forecast | $-0.06 | $-0.06 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $1.65 | $-0.21 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.54 | $-0.14 | $-1.57 | $-0.59 | $-0.52 | $0.36 | $5.69 |
| Low Forecast | $-0.06 | $-0.06 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $1.65 | $-0.21 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.80 | $-0.21 | $-2.36 | $-0.90 | $-0.78 | $0.24 | $3.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.93% | 2.15% | 1.79% | 1.17% | 1.40% | 3.19% | 4.46% | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Summit Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SMMT previous annual EPS of $NaN (undefined).
Summit Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.58 | $17.50 | 2917.24% | Buy |
| ELEV | Elevation Oncology | $0.60 | $9.00 | 1400.00% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| NKTX | Nkarta | $5.39 | $21.60 | 300.74% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| ZURA | Zura Bio | $3.88 | $5.00 | 28.87% | Buy |
| SMMT | Summit Therapeutics | $26.22 | $29.50 | 12.51% | Buy |
SMMT Forecast FAQ
Is Summit Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Summit Therapeutics (SMMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of SMMT's total ratings.
What is SMMT's price target?
Summit Therapeutics (SMMT) average price target is $29.5 with a range of $14 to $45, implying a 12.55% from its last price of $26.21. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Summit Therapeutics stock go up soon?
According to Wall Street analysts' prediction for SMMT stock, the company can go up by 12.55% (from the last price of $26.21 to the average price target of $29.5), up by 71.69% based on the highest stock price target, and down by -46.59% based on the lowest stock price target.
Can Summit Therapeutics stock reach $40?
SMMT's highest twelve months analyst stock price target of $45 supports the claim that Summit Therapeutics can reach $40 in the near future.
What is Summit Therapeutics's current price target trend?
1 Wall Street analyst forecast a $45 price target for Summit Therapeutics (SMMT) this month, up 71.69% from its last price of $26.21. Compared to the last 3 and 12 months, the average price target increased by 71.69% and decreased by -14.80%, respectively.
What are Summit Therapeutics's analysts' financial forecasts?
Summit Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-143M (high $-137M, low $-143M), average SG&A $0 (high $0, low $0), and average EPS is $-0.202 (high $-0.194, low $-0.202). SMMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-159M (high $-159M, low $-159M), average SG&A $0 (high $0, low $0), and average EPS is $-0.225 (high $-0.225, low $-0.225).
Did the SMMT's actual financial results beat the analysts' financial forecasts?
Based on Summit Therapeutics's last annual report (Dec 2020), the company's revenue was $860K, which missed the average analysts forecast of $17.15M by -94.99%. Apple's EBITDA was $-51.475M, missing the average prediction of $-1.912B by -97.31%. The company's net income was $-52.697M, missing the average estimation of $-2.117B by -97.51%. Apple's SG&A was $19.23M, missing the average forecast of $305.38M by -93.70%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.433 by 75.63%. In terms of the last quarterly report (Sep 2021), Summit Therapeutics's revenue was $1.31M, beating the average analysts' forecast of $1.71K by 76629.19%. The company's EBITDA was $-18.967M, missing the average prediction of $-24.723M by -23.28%. Summit Therapeutics's net income was $-19.712M, missing the average estimation of $-25.546M by -22.84%. The company's SG&A was $5.66M, beating the average forecast of $30.38K by 18537.87%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.215 by -6.83%